Document is current
Any future updates will be listed below
-
Authors
Daihom, Baher A. https://orcid.org/0000-0003-3264-3564
Abdelhakk, Hala M. https://orcid.org/0009-0004-1190-4117
Maniruzzaman, Mohammed https://orcid.org/0000-0002-3373-5586
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 7 August 2025
First Online: 3 September 2025
Declarations
:
: The authors declare the following conflict of interest. Mohammed Maniruzzaman (M.M.), an author of this manuscript, holds stock in, serves on a scientific advisory board for, or is a consultant for CoM3D Ltd. (Surrey, UK), DosePlus Therapeutics, Inc. (Princeton, NJ, USA), SmarGic Tech LLC (Oxford, MS, USA), and Septum Solutions LLC (Houston, TX, USA). The terms of this arrangement have been reviewed and approved by the University of Texas at Austin and the University of Mississippi (Ole Miss) in accordance with their policies on objectivity in research. The companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.
